<code id='C22850CD56'></code><style id='C22850CD56'></style>
    • <acronym id='C22850CD56'></acronym>
      <center id='C22850CD56'><center id='C22850CD56'><tfoot id='C22850CD56'></tfoot></center><abbr id='C22850CD56'><dir id='C22850CD56'><tfoot id='C22850CD56'></tfoot><noframes id='C22850CD56'>

    • <optgroup id='C22850CD56'><strike id='C22850CD56'><sup id='C22850CD56'></sup></strike><code id='C22850CD56'></code></optgroup>
        1. <b id='C22850CD56'><label id='C22850CD56'><select id='C22850CD56'><dt id='C22850CD56'><span id='C22850CD56'></span></dt></select></label></b><u id='C22850CD56'></u>
          <i id='C22850CD56'><strike id='C22850CD56'><tt id='C22850CD56'><pre id='C22850CD56'></pre></tt></strike></i>

          Home / Wikipedia / leisure time

          leisure time


          leisure time

          author:explore    Page View:57
          translucent 3D DNA helix with blue and purple background
          Adobe

          Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

          The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

          advertisement

          “We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In